In addition, bort induces lysosomal degradation of C‐KIT protein32 and induces the degradation of FLT3‐ITD in an autophagy‐dependent manner,33 suggesting that bort might has the clinical therapeutic application in C‐KIT‐driven AML and AML patients with positive FLT3‐ITD mutation. This evidence concerns the gene KIT and acute myeloid leukemia.